Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Find Stocks Tailored to Your Trading Interests

benzingaproreview-1-1280x720

acf/call-to-action

<p class="has-text-align-left"><strong><a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a></strong></p>





<p></p>

Compare Investing Brokers (USE THIS ONE)

acf/widget-container

acf/compare-products

Plus500 Yield

IBKR Stocks

public.com

Moomoo

Webull

<p><strong><a href="https://share.hsforms.com/1kQ-soZmmTRqplsRXp5Zfpw1npzh">Claim Exclusive Offers</a></strong></p>





<p></p>

Compare Crypto Brokers Homepage

Plus500 Crypto

Kraken

Webull Crypto

FxGlory

eToro

Uphold Crypto

Compare Brokers Table – Benzinga.com

Illumina

Pfizer

Johnson & Johnson

Amgen

Bristol-Myers Squibb

Bristol-Myers Squibb Company Common Stock

Merck & Co

Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Narumi Nakagiri's

cisco_systems_shutter3

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our<a href="https://www.benzinga.com/analyst-stock-ratings"> analyst ratings page.</a></p>



<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5809becc846faa000106ad2b/stephen-bersey">HSBC analyst Stephen Bersey</a> upgraded the rating for <strong>Cisco Systems, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Hold to Buy, while raising the price target from $46 to $58. Cisco shares gained 6.8% to close at $48.53 on Thursday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Williams Trading analyst Sam Poser upgraded <strong>NIKE, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Sell to Buy and boosted the price target from $67 to $93. Nike shares gained 5.1% to close at $82.50 on Thursday. <a href="https://www.benzinga.com/quote/CNKESCO/analyst-ratings">See how other analysts view this sto</a>ck.</li>



<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6331beac10b15f0001b58380/c-j%20muse">Cantor Fitzgerald analyst C J Muse </a>upgraded the rating for <strong>Teradyne, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) from Neutral to Overweight and announced a $160 price target. Teradyne shares gained 5.2% to close at $131.73 on Thursday. <a href="https://www.benzinga.com/quote/TER/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Piper Sandler analyst Harsh Kumar upgraded <strong>Microchip Technology Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from Neutral to Overweight, while increasing the price target from $90 to $100. Microchip shares gained 4.1% to settle at $81.30 on Thursday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Daiwa Capital analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6331beac10b15f0001b58380/c-j%20muse">Narumi Nakagiri</a> upgraded the rating for <strong>Illumina, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Neutral to Buy and boosted the price target from $120 to $154. Illumina shares gained 5.3% to close at $128.80 on Thursday. See how other analysts view this stock. S<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>



<p>Considering buying CSCO stock? Here&#8217;s what analysts think:</p>



<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-1024x579.png" alt="" class="wp-image-498819" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16082653/image-1-47.png 1257w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



<p><strong>Read More: </strong></p>



<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40394036/jim-cramer-recommends-buying-clorox-ceo-has-done-remarkable-job">Jim Cramer Recommends Buying Clorox: &#8216;CEO Has Done Remarkable Job&#8217;</a></strong></li>
</ul>

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CSCO

ILMN

MCHP

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Alibaba.Fall20221.site_

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a></p>



<ul>
<li>Piper Sandler raised the price target for <strong>Globant S.A.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) from $238 to $240. Piper Sandler analyst Arvind Ramnani reiterated an Overweight rating. Globant shares gained 1.7% to close at $194.37 on Thursday. <a href="https://www.benzinga.com/quote/GLOB/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Daiwa Capital increased the price target for <strong>Illumina, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from $120 to $154. Daiwa Capital analyst Narumi Nakagiri upgraded the stock from Neutral to Buy. Illumina shares gained 5.3% to close at $128.80 on Thursday.<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings"> See how other analysts view this stock.</a></li>



<li>Piper Sandler boosted <strong>Microchip Technology Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) price target from $90 to $100. Piper Sandler analyst Harsh Kumar upgraded the stock from Neutral to Overweight. Microchip shares rose 4.1% to close at $81.30 on Thursday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Morgan Stanley cut the price target for <strong>The Charles Schwab Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) from $71 to $70. Morgan Stanley analyst Michael Cyprys maintained an Equal-Weight rating. Charles Schwab shares fell 0.2% to close at $65.23 on Thursday. <a href="https://www.benzinga.com/quote/CHW/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Telsey Advisory Group boosted <strong>Walmart Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) price target from $75 to $82. Telsey Advisory Group analyst Joe Feldman maintained an Outperform rating. Walmart shares gained 6.6% to close at $73.18 on Thursday. <a href="https://www.benzinga.com/quote/WMT/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Baird increased <strong>Amcor plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>) price target from $10 to $11. Baird analyst Ghansham Panjabi maintained a Neutral rating. Amcor shares gained 1.8% to close at $10.85 on Thursday. <a href="https://www.benzinga.com/quote/AMCR/analyst-ratings">See how other analysts view this stock.</a></li>



<li>Baird increased the price target for <strong>Alibaba Group Holding Limited</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) from $85 to $88. Baird analyst Colin Sebastian maintained an Outperform rating. Alibaba shares rose 0.1% to close at $79.54 on Thursday. <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">See how other analysts view this stock.</a></li>



<li>B of A Securities raised <strong>Deere &amp; Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) price target from $400 to $410. B of A Securities analyst Ross Gilardi maintained a Neutral rating. Deere shares gained 6.3% to close at $373.26 on Thursday.<a href="https://www.benzinga.com/quote/DE/analyst-ratings"> See how other analysts view this stock.</a></li>



<li>Wells Fargo boosted <strong>Fox Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) price target from $29 to $46. Wells Fargo analyst Steven Cahall upgraded the stock from Underweight to Overweight. Fox shares fell 0.2% to close at $38.99 on Thursday.<a href="https://www.benzinga.com/quote/FOXA/analyst-ratings"> See how other analysts view this stock.</a></li>



<li>Benchmark cut <strong>JD.com, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) price target from $55 to $47. Benchmark analyst Fawne Jiang maintained a Buy rating. JD.com shares gained 4.3% to close at $27.00 on Thursday. <a href="https://www.benzinga.com/quote/JD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>



<p>Considering buying BABA stock? Here&#8217;s what analysts think:</p>



<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="569" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16074215/image-1-46-1024x569.png" alt="" class="wp-image-498708" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16074215/image-1-46-1024x569.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16074215/image-1-46-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16074215/image-1-46-768x427.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/16074215/image-1-46.png 1235w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Price Target

AMCR

BABA

FOXA

GLOB

SCHW

Alibaba To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Friday

analyst ratings image

<p>In the last three months, 14 analysts have published ratings on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $183.5, a high estimate of $215.00, and a low estimate of $150.00. This current average represents a 0.89% decrease from the previous average price target of $185.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722348093_0.png" alt="price target chart" /></p>

<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Johnson &amp; Johnson's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Johnson &amp; Johnson analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
<p>Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.</p>
<h3>Johnson &amp; Johnson: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Johnson &amp; Johnson displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>4.31%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Johnson &amp; Johnson's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>20.88%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.62%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Johnson &amp; Johnson's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.65%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.58</strong>, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

A Closer Look at 14 Analyst Recommendations For Johnson &amp; Johnson

<p>Ratings for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<p>Analysts have set 12-month price targets for Amgen, revealing an average target of $291.91, a high estimate of $326.00, and a low estimate of $240.00. This upward trend is apparent, with the current average reflecting a 5.6% increase from the previous average price target of $276.43.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1706547621_0.png" alt="price target chart" /></p>

<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$314.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$320.00</td>
<td>-</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$326.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>-</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$240.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$256.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$320.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$268.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$256.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$291.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Amgen compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Amgen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Amgen analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Amgen</h2>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<h3>A Deep Dive into Amgen's Financials</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Amgen showcased positive performance, achieving a revenue growth rate of <strong>3.77%</strong> as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>25.06%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>23.97%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Amgen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.91%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>7.9</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

AMGN

Expert Outlook: Amgen Through The Eyes Of 11 Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.77, a high estimate of $84.00, and a low estimate of $50.00. A 6.82% drop is evident in the current average compared to the previous average price target of $65.22. </p>
<p><img src="https://www.benzinga.com/files/images/story/2023/1703678409_0.png" alt="price target chart" /></p>

<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Bristol-Myers Squibb by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Narumi Nakagiri</td>
<td>Daiwa Capital</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$69.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Hold</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$56.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>-</td>
</tr>
</tbody>
</table>

<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Bristol-Myers Squibb's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bristol-Myers Squibb's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BMY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bristol-Myers Squibb analyst ratings.</strong></a></p>
<h2>All You Need to Know About Bristol-Myers Squibb</h2>
<p>Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.</p>
<h3>Key Indicators: Bristol-Myers Squibb's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Bristol-Myers Squibb's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately <strong>-2.25%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Bristol-Myers Squibb's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>17.58%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Bristol-Myers Squibb's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>6.32%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Bristol-Myers Squibb's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.09%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Bristol-Myers Squibb's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.35</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

Analyst Expectations For Bristol-Myers Squibb&#39;s Future

Analyst Ratings Newsletter

Don't Miss Your Daily Analyst Rating Email!!!

acf/newsletter-subscription-box

acf/raptive-ad-placement

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Narumi Nakagiri's Stock Ratings

Daiwa Capital Analyst

Overall Average Return

Smart Score

Overall Average Return Percentile

Number of Ratings

Recent Analyst Stock Rating News